Ñо¿ÐÔ°¢¶û´Äº£Ä¬²¡ÖÎÁÆLECANEMAB»ñµÃÃÀ¹úFDA¿ìËÙÉêÇëͨµÀÖ¸¶¨

ÈÕ±¾¶«¾©ºÍÃÀ¹úÂíÈøÖîÈûÖݽ£ÇÅÊÐ £¬2021Äê12ÔÂ24ÈÕ-À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ磨×ܲ¿£º¶«¾© £¬CEO£ºÄÚÌÙÇç·ò £¬ÒÔϼò³Æ¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡±£©ºÍ²³½¡¹«Ë¾£¨Nasdaq£ºBIIB £¬¹«Ë¾×ܲ¿£ºÂíÈøÖîÈûÖݽ£ÇÅÊÐ £¬CEO£ºMichel Vounatsos £¬ÒÔϼò³Æ¡°²³½¡¡±£©Ðû²¼ £¬lecanemab ÊÇÒ»ÖÖÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡(AD)µÄÑо¿ÐÔҩΦµí·ÛÑùÂÑ°×£¨A¦Â£©Ô­ÏËά¿¹Ìå £¬ÒÑ»ñµÃÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö (FDA)µÄ¿ìËÙÉêÇëͨµÀÖ¸¶¨¡£FDAÓÚ2021Äê6ÔÂÊÚÓèlecanemabÍ»ÆÆÐÔÁÆ·¨³Æν¡£ Í»ÆÆÐÔÁÆ·¨³ÆνºÍ¿ìËÙÉêÇëͨµÀÖ¸¶¨ÊÇFDAµÄÁ½¸ö¼Æ»® £¬Ö¼ÔÚ´Ù½øºÍ¼Ó¿ìÐÂÒ©µÄ¿ª·¢ £¬ÒÔÂú×ãÄÇЩδ±»Âú×ãµÄÒ½ÁÆÐèÇóÖУ¨ÀýÈ磺°¢¶û´Äº£Ä¬²¡£©ÖÎÁÆÑÏÖØ»òΣ¼°ÉúÃüµÄ¼²²¡ £¬²¢ÌṩÓëFDAƵ·±»¥¶¯µÄ»ú»á¡£

2021Äê9Ô £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿ªÊ¼Æ¾¾Ý¼ÓËÙÅú׼ͨµÀÏòFDA¹ö¶¯Ìá½»lecanemabµÄÉúÎïÖƼÁÐí¿ÉÉêÇ루BLA£©¡£BLAÖ÷Òª»ùÓÚ2bÆÚÁÙ´²Ñо¿(Study 201)µÄÁÙ´²¡¢ÉúÎï±êÖ¾ÎïºÍÄþ¾²ÐÔÊý¾Ý £¬Õë¶ÔÔçÆÚADºÍÈ·ÕïµÄµí·ÛÑùÂѰײ¡ÀíѧºÍ°üÂÞÈý²¿ÃÅ£¨·ÇÁÙ´²¡¢ÁÙ´²ºÍCMC£©µÄ·ÇÁÙ´²ºÍÁÙ´²ÉêÇëÒѾ­Ìá½»¡£lecanemab 2bÆÚÑо¿½á¹û±íÃ÷ £¬ÔÚ¶à¸öÁÙ´²ÖÕµãÖÐA¦Â°ß¿é¸ß¶È½µµÍ¶øÇÒÁÙ´²Ï½µÁ¬Ðø¼õÉÙ¡£ÔÚÑо¿201ÖÐ £¬A¦Â°ß¿é¼õÉÙˮƽÓë¶ÔÁÙ´²ÖÕµãµÄÓ°ÏìÖ®¼äµÄÏà¹ØÐÔ½øÒ»²½Ö§³ÖA¦Â×÷ΪÌæ´úÖյ㠣¬¿ÉÒÔºÏÀíµØÔ¤²âÁÙ´²»ñÒæ¡£

lecanemab Clarity ADÔçÆÚADµÄ3ÆÚÁÙ´²Ñо¿ÕýÔÚ½øÐÐÖÐ £¬²¢ÓÚ2021Äê3ÔÂÍê³ÉÁËÕÐļ £¬¹²ÓÐ1,795Ãû»¼Õß¡£FDAÒѾ­Í¬ÒâClarity ADµÄ½á¹ûÔÚÍê³Éºó¿ÉÒÔ×÷ΪÑéÖ¤Ñо¿À´ÑéÖ¤ lecanemabµÄÁÙ´²»ñÒæ¡£°üÂÞÀ´×ÔClarity ADµÄÒþ±ÎÄþ¾²Êý¾ÝÒÔÖ§³ÖÕýÔÚ½øÐеĹö¶¯Ìá½»¡£ÁíÒ»ÏîIIIÆÚÁÙ´²Ñо¿AHEAD 3-45ÕýÔÚÆÀ¹ÀlecanemabÖÎÁÆÁÙ´²Ç°ADºÍµí·ÛÑùÂÑ°×Éý¸ßµÄ¼ÓÈëÕßÒÔ¼°ÔçÆÚÁÙ´²Ç°ADºÍÖжȵí·ÛÑùÂѰ׵ļÓÈëÕßµÄÁÆЧ¡£´ËÍâ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾»¹Æô¶¯ÁËlecanemabƤϸøÒ©µÄIÆÚÑо¿¡£

°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖÑÏÖصġ¢½øÐÐÐԵĺͻÙÃðÐԵļ²²¡ £¬ÖÎÁÆÑ¡ÔñºÜÉÙ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÖÂÁ¦ÓÚΪÔçÆÚAD»¼Õß¡¢ËûÃǵļÒÈ˺ÍÆÚ´ýËûÃǵÄÒ½ÁÆרҵÈËÊ¿´øÀ´ÐµÄÖÎÁÆÑ¡Ôñ¡£